Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 22;10(4):00048-2024.
doi: 10.1183/23120541.00048-2024. eCollection 2024 Jul.

Dupilumab-associated hypereosinophilia in severe asthma

April Strong  1   2 , Tiffany Lin  1   2 , Asger Sverrild  3 , Anna Mackay  1 , Joy Lee  1   4   5 , Celia Zubrinich  1 , Jonathan Pham  1   6 , Julian Bosco  1   5 , Eve Denton  1   5 , Monique Dols  1 , Robert G Stirling  1   5 , Eli Dabscheck  1   5 , Jhanavi Iyer  1 , Andrew Gillman  1 , Mark Hew  1   4
Affiliations

Dupilumab-associated hypereosinophilia in severe asthma

April Strong et al. ERJ Open Res. .

Abstract

Dupilumab has been associated with adverse reactions including symptomatic hypereosinophilia. This study reports the incidence of dupilumab-related eosinophilia and adverse reactions in severe asthma patients at an Australian tertiary centre. https://bit.ly/3JgZ5Ya.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Unrelated to this study, in the past 36 months, A. Sverrild has received research grants paid to their employer from AstraZeneca, and speaker fees from AstraZeneca and Sanofi. A. Sverrild serves on advisory boards for GlaxoSmithKline and Sanofi-Regeneron with honoraria made to their institution. Conflict of interest: Unrelated to this study, J. Lee has received speaker fees from AstraZeneca, Sanofi and GSK, as well as serving on the board of the National Allergy Centre of Excellence. Conflict of interest: Unrelated to this study, in the past 36 months, C. Zubrinich has received speaker fees and grants from Novartis, Mylan, Seqirus, Inovating and Inside Practice. Conflict of interest: Unrelated to this study, E. Denton declares project grants to her institution from AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Teva and Seqirus, and speaker fees from Sanofi. Conflict of interest: Unrelated to this study, M. Hew has received grants and personal fees from GlaxoSmithKline, AstraZeneca, Sanofi, Novartis, Teva and Chiesi, all paid to his employer Alfred Health. Conflict of interest: The remaining authors have nothing to disclose.

References

    1. Wenzel S, Ford L, Pearlman D, et al. . Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368: 2455–2466. doi:10.1056/NEJMoa1304048 - DOI - PubMed
    1. Rabe KF, Nair P, Brusselle G, et al. . Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018; 378: 2475–2485. doi:10.1056/NEJMoa1804093 - DOI - PubMed
    1. Castro M, Corren J, Pavord ID, et al. . Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018; 378: 2486–2496. doi:10.1056/NEJMoa1804092 - DOI - PubMed
    1. Australian Government . The Pharmaceutical Benefits Scheme. www.pbs.gov.au/medicine/item/12291X-12309W-12313C-12316F-12318H. Date last accessed: 28 May 2023.
    1. Bachert C, Han JK, Desrosiers M, et al. . Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019; 394: 1638–1650. doi:10.1016/S0140-6736(19)31881-1 - DOI - PubMed

LinkOut - more resources